Molecular-targeted therapy for tumor-agnostic mutations in acute myeloid leukemia

HIGHLIGHTS

• who: Hironori Arai and colleagues from the Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Iidacho, Japan have published the research work: Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia, in the Journal: Biomedicines 2022, 3008 of /2022/
• what: The authors focused on representative tumor-agnostic mutations such as the TP53 KIT KRAS BRCA1 ATM JAK2 NTRK3 FGFR3 and EGFR genes referring to a CGP study conducted in Japan and the authors considered the possibility of developing molecular-targeted therapies for AML with tumor-agnostic mutations. The aim of this . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.